About E3 ubiquitin-protein ligase RNF146
E3 ubiquitin-protein ligase RNF146 (RNF146) is a protein
from Homo sapiens identified by UniProt accession
Q9NTX7, 359 residues long.
MolForge cross-references it against 0 known binders and
108 disease associations.
Target properties
| Protein name | E3 ubiquitin-protein ligase RNF146 |
|---|
| UniProt accession | Q9NTX7 |
|---|
| Gene | RNF146 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 359 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (108)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.35
- mean corpuscular volume · score 0.34
- mean reticulocyte volume · score 0.31
- ovarian cancer · score 0.23
- breast adenocarcinoma · score 0.23
- waist-hip ratio · score 0.12
- esophageal cancer · score 0.10
- breast carcinoma · score 0.10
- high density lipoprotein cholesterol measurement · score 0.08
- heel bone mineral density · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9NTX7-F1 | alphafold | PREDICTED | 66.60 | — |
Amino-acid sequence (359 residues)
MMAGCGEIDH SINMLPTNRK ANESCSNTAP SLTVPECAIC LQTCVHPVSL PCKHVFCYLC VKGASWLGKR CALCRQEIPE DFLDKPTLLS PEELKAASRG NGEYAWYYEG RNGWWQYDER TSRELEDAFS KGKKNTEMLI AGFLYVADLE NMVQYRRNEH GRRRKIKRDI IDIPKKGVAG LRLDCDANTV NLARESSADG ADSVSAQSGA SVQPLVSSVR PLTSVDGQLT SPATPSPDAS TSLEDSFAHL QLSGDNTAER SHRGEGEEDH ESPSSGRVPA PDTSIEETES DASSDSEDVS AVVAQHSLTQ QRLLVSNANQ TVPDRSDRSG TDRSVAGGGT VSVSVRSRRP DGQCTVTEV
Explore E3 ubiquitin-protein ligase RNF146 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets